Timber Pharma gains on positive results from skin disease treatment study

Trex Wind-Down

07/10/2021 15:18

** Shares of biopharmaceutical company  TMBR.N  up 2.9% at
85 cents
    ** Co announces positive results from its study evaluating
TMB-001, an investigational drug for patients with moderate to
severe congenital ichthyosis (CI)  urn:newsml:reuters.com:*:nGNE91FpzM
    ** CI is a group of rare, genetic disorder that lead to dry,
thickened and scaling skin
    ** Data demonstrates reduction in targeted and overall
severity of CI in patients treated with TMB-001
    ** Co plans for end of Phase 2 meeting with U.S. Food and
Drug Administration in the beginning of 2022
    ** There are no approved medications for CI and the current
common management of this chronic disease is focused on reducing
scaling or improving skin lubrication
    ** Including session gains, stock up ~12% YTD

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))